118 related articles for article (PubMed ID: 24789658)
1. Distinct regulatory effect of the p34SEI-1 oncoprotein on cancer metastasis in HER2/neu-positive and -negative cells.
Jung S; Ohk J; Jeong D; Li C; Lee S; Duan J; Kim C; Lim JS; Yang Y; Kim KI; Lee MS
Int J Oncol; 2014 Jul; 45(1):189-96. PubMed ID: 24789658
[TBL] [Abstract][Full Text] [Related]
2. p34SEI-1 inhibits apoptosis through the stabilization of the X-linked inhibitor of apoptosis protein: p34SEI-1 as a novel target for anti-breast cancer strategies.
Hong SW; Kim CJ; Park WS; Shin JS; Lee SD; Ko SG; Jung SI; Park IC; An SK; Lee WK; Lee WJ; Jin DH; Lee MS
Cancer Res; 2009 Feb; 69(3):741-6. PubMed ID: 19176394
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic function of p34SEI-1 via NEDD4‑1‑mediated PTEN ubiquitination/degradation and activation of the PI3K/AKT pathway.
Jung S; Li C; Jeong D; Lee S; Ohk J; Park M; Han S; Duan J; Kim C; Yang Y; Kim KI; Lim JS; Kang YS; Lee MS
Int J Oncol; 2013 Nov; 43(5):1587-95. PubMed ID: 23970032
[TBL] [Abstract][Full Text] [Related]
4. Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma.
Tokunaga E; Oki E; Kimura Y; Yamanaka T; Egashira A; Nishida K; Koga T; Morita M; Kakeji Y; Maehara Y
Breast Cancer Res Treat; 2007 Mar; 101(3):249-57. PubMed ID: 17006756
[TBL] [Abstract][Full Text] [Related]
5. p34SEI-1 inhibits doxorubicin-induced senescence through a pathway mediated by protein kinase C-delta and c-Jun-NH2-kinase 1 activation in human breast cancer MCF7 cells.
Lee SL; Hong SW; Shin JS; Kim JS; Ko SG; Hong NJ; Kim DJ; Lee WJ; Jin DH; Lee MS
Mol Cancer Res; 2009 Nov; 7(11):1845-53. PubMed ID: 19903772
[TBL] [Abstract][Full Text] [Related]
6. The nuclear protein p34SEI-1 regulates the kinase activity of cyclin-dependent kinase 4 in a concentration-dependent manner.
Li J; Melvin WS; Tsai MD; Muscarella P
Biochemistry; 2004 Apr; 43(14):4394-9. PubMed ID: 15065884
[TBL] [Abstract][Full Text] [Related]
7. Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway.
Way TD; Kao MC; Lin JK
J Biol Chem; 2004 Feb; 279(6):4479-89. PubMed ID: 14602723
[TBL] [Abstract][Full Text] [Related]
8. [The effect of HER2/neu overexpression on p53 gene expression, cell proliferation and sensitivity to gamma-irradiation via the PI3K/Akt pathway in breast cancer cell MCF7].
Zheng L; Ren JQ; Chen Q; Zhang HP; Zhu HG
Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):594-7. PubMed ID: 15634518
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients.
Xia W; Chen JS; Zhou X; Sun PR; Lee DF; Liao Y; Zhou BP; Hung MC
Clin Cancer Res; 2004 Jun; 10(11):3815-24. PubMed ID: 15173090
[TBL] [Abstract][Full Text] [Related]
10. NMR uncovers direct interaction between human NEDD4-1 and p34
Shrestha P; Yun JH; Ko YJ; Yeon KJ; Kim D; Lee H; Jin DH; Nam KY; Yoo HD; Lee W
Biochem Biophys Res Commun; 2017 Aug; 490(3):984-990. PubMed ID: 28666866
[TBL] [Abstract][Full Text] [Related]
11. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
[TBL] [Abstract][Full Text] [Related]
12. Degradation of HER2/neu by ANT2 shRNA suppresses migration and invasiveness of breast cancer cells.
Jang JY; Jeon YK; Kim CW
BMC Cancer; 2010 Jul; 10():391. PubMed ID: 20650008
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
Piechocki MP; Yoo GH; Dibbley SK; Lonardo F
Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894
[TBL] [Abstract][Full Text] [Related]
14. Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways.
Niu G; Carter WB
Cancer Res; 2007 Feb; 67(4):1487-93. PubMed ID: 17308086
[TBL] [Abstract][Full Text] [Related]
15. Magnolol down-regulates HER2 gene expression, leading to inhibition of HER2-mediated metastatic potential in ovarian cancer cells.
Chuang TC; Hsu SC; Cheng YT; Shao WS; Wu K; Fang GS; Ou CC; Wang V
Cancer Lett; 2011 Dec; 311(1):11-9. PubMed ID: 21757288
[TBL] [Abstract][Full Text] [Related]
16. The Ste20-like kinase SLK is required for ErbB2-driven breast cancer cell motility.
Roovers K; Wagner S; Storbeck CJ; O'Reilly P; Lo V; Northey JJ; Chmielecki J; Muller WJ; Siegel PM; Sabourin LA
Oncogene; 2009 Aug; 28(31):2839-48. PubMed ID: 19525980
[TBL] [Abstract][Full Text] [Related]
17. An inherent role of integrin-linked kinase-estrogen receptor alpha interaction in cell migration.
Acconcia F; Manavathi B; Mascarenhas J; Talukder AH; Mills G; Kumar R
Cancer Res; 2006 Nov; 66(22):11030-8. PubMed ID: 17108142
[TBL] [Abstract][Full Text] [Related]
18. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.
Asanuma H; Torigoe T; Kamiguchi K; Hirohashi Y; Ohmura T; Hirata K; Sato M; Sato N
Cancer Res; 2005 Dec; 65(23):11018-25. PubMed ID: 16322251
[TBL] [Abstract][Full Text] [Related]
19. GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation.
Bai T; Luoh SW
Carcinogenesis; 2008 Mar; 29(3):473-9. PubMed ID: 17916906
[TBL] [Abstract][Full Text] [Related]
20. Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival.
Troussard AA; McDonald PC; Wederell ED; Mawji NM; Filipenko NR; Gelmon KA; Kucab JE; Dunn SE; Emerman JT; Bally MB; Dedhar S
Cancer Res; 2006 Jan; 66(1):393-403. PubMed ID: 16397254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
